Wilson Sonsini - ECVC

Biotech

Our Industry Coverage

Innovative and passionate; that's how we describe our biotech companies. From cutting-edge biopharmaceutical therapies to bioinformatics, we support our clients’ pursuit of excellence. Through their relentless drive to innovate, we work to protect pivotal intellectual property, navigate regulatory environments, and advise on financing strategy.

Industry Highlights

Celebrating our founders’ successes

2024

Kumquat Biosciences and Takeda Enter into Strategic Collaboration and Global License Agreement

Biotechnology

2023

DTx Pharma Announces Acquisition by Novartis

Biotechnology

2023

XinThera Announces Acquisition by Gilead Sciences

Biotechnology

2023

Aspect Biosystems Announces $2.7 Billion Collaboration with Novo Nordisk

Biotechnology

2022

Tenaya Therapeutics Raises Approximately $75 Million in Public Stock Offering

Biotechnology

2022

GSK Completes Acquisition of Sierra Oncology

Biopharmaceutical

2022

Arcellx, Inc. Raises $124 Million IPO

Biotechnology

2021

Ventyx Biosciences Closes IPO at $175 Million

Biotechnology, Pharmaceuticals

2021

Tenaya Therapeutics Completes IPO Worth $207 Million

Biotechnology

2021

Kinnate Biopharma Inc. Raises $276 Million IPO

Drug Discovery, Pharmaceuticals

2020

ALX Oncology Holdings Inc. Closes IPO at $186 Million

Immuno-Oncology

2020

ORIC Pharmaceuticals Raises $138 Million IPO

Pharmaceuticals

2020

Applied Molecular Transport Closes IPO at $154 Million

Pharmaceuticals

2019

IGM Biosciences Launches IPO

Biotechnology

Attorneys

focused
on this
industry

See all ECVC attorneys

Mark
Fitzgerald

See all ECVC attorneys

recent news

we want to share
with you

Wilson Sonsini Advises Neurode on Pre-Seed Financing

Wilson Sonsini Advises Neurode on Pre-Seed Financing

Client Highlights09/20/24
Wilson Sonsini Advises GC Therapeutics on $65 Million Series A
See all news
See all news

other industries

we have covered